Scilex Holding Company Common Stock (SCLX) Stock Price

SCLXStock

$5.43−70.21%52W

Market Cap$38.20M

P/E—

PEG Ratio—

Div yield—

Beta1.76

SCLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-45.39%

Price vs S&P 500 (4W)-18.77%

VGM Score39.19

P/CF (Annual)12.40x

Book Value / Share (Quarterly)$0.07

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-7.34%

Cash Flow / Share (Quarterly)$-6.10

Price vs S&P 500 (YTD)-68.31%

Gross Margin (TTM)55.50%

Net Profit Margin (TTM)-1414.57%

EPS (TTM)$-48.45

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-48.45

Revenue Growth (5Y)5.13%

EPS (Annual)$-32.51

ROI (Annual)-64.46%

Gross Margin (Annual)64.97%

Net Profit Margin (5Y Avg)-380.55%

Cash / Share (Quarterly)$0.08

Revenue Growth QoQ (YoY)-22.78%

ROA (Last FY)-98.29%

Revenue Growth TTM (YoY)-28.55%

EBITD / Share (TTM)$-41.43

Operating Margin (TTM)-1159.66%

Cash Flow / Share (Annual)$-1.84

P/B Ratio4.51x

P/B Ratio (Quarterly)78.88x

Net Income / Employee (Annual)$-10,551,000

EV / Revenue (TTM)4.37x

Net Interest Coverage (TTM)-17.27x

ROA (TTM)-150.54%

EPS Incl Extra (Annual)$-32.51

Current Ratio (Annual)0.08x

Quick Ratio (Quarterly)0.05x

3-Month Avg Trading Volume0.11M

52-Week Price Return-70.21%

EV / Free Cash Flow (Annual)6.16x

Revenue / Employee (TTM)$929,600

Tangible BV / Share (Quarterly)$-2.27

P/S Ratio (Annual)1.56x

Asset Turnover (Annual)0.08x

52-Week High$34.27

Operating Margin (5Y Avg)-350.60%

EPS Excl Extra (Annual)$-32.51

CapEx CAGR (5Y)254.39%

26-Week Price Return-33.46%

Quick Ratio (Annual)0.05x

13-Week Price Return-24.69%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.07x

Enterprise Value$137.97M

Revenue / Share Growth (5Y)75.07%

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$889,800

Inventory Turnover (Annual)2.93x

Pretax Margin (Annual)-1236.33%

Cash / Share (Annual)$1.56

3-Month Return Std Dev185.63%

Gross Margin (5Y Avg)72.39%

Net Income / Employee (TTM)$-13,150,500

ROE (Last FY)-64.46%

Net Interest Coverage (Annual)-1.52x

EPS Basic Excl Extra (Annual)$-32.51

P/FCF (TTM)2.72x

Receivables Turnover (TTM)2.72x

EV / Free Cash Flow (TTM)27.02x

Total Debt / Equity (Quarterly)3.31x

EPS Incl Extra (TTM)$-48.45

Receivables Turnover (Annual)1.45x

P/S Ratio (TTM)1.50x

Pretax Margin (5Y Avg)-390.66%

Revenue / Share (Annual)$2.74

Tangible BV / Share (Annual)$-0.13

Forward P/E2.64x

Price vs S&P 500 (52W)-88.77%

Year-to-Date Return-55.49%

5-Day Price Return-4.06%

EPS Normalized (Annual)$-32.51

ROA (5Y Avg)-85.99%

Net Profit Margin (Annual)-1185.78%

Month-to-Date Return-18.53%

Cash Flow / Share (TTM)$-1.13

EBITD / Share (Annual)$-31.63

Operating Margin (Annual)-1168.01%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)11.26x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-48.45

P/B Ratio (Annual)15.56x

Inventory Turnover (TTM)4.21x

Pretax Margin (TTM)-1469.71%

Book Value / Share (Annual)$0.26

Price vs S&P 500 (13W)-26.64%

Beta1.76x

P/FCF (Annual)2.52x

Revenue / Share (TTM)$4.59

ROE (TTM)-130.91%

52-Week Low$4.20

vGradeB

gGradeD

mGradeD

vgmGradeD

SCLX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Apr 10, 2026	-$0.47	-$1.17	-149.28%(-$0.70)
Q3 2025	Nov 14, 2025	-$0.41	-$21.29	-5093.41%(-$20.88)
Q2 2025	Aug 13, 2025	-$0.91	-$7.42	-715.38%(-$6.51)
Q1 2025	May 14, 2025	-$0.01	-$1.73	-17202.00%(-$1.72)

SCLX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.17

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SCLXScilex Holding Company Common Stock	B	D	D	$5.43
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Scilex Holding Company Common Stock

Scilex Holding Co develops non-opioid pain management therapeutics for acute and chronic pain conditions. Commercial products include ZTlido (lidocaine topical system for postherpetic neuralgia) and Gloperba (colchicine oral solution for gout flare prevention). The clinical pipeline comprises SP-102 (corticosteroid gel for epidural injection), SP-103 (enhanced lidocaine formulation), and SP-104 (low-dose naltrexone capsule).